看见一个 Expert Review of Anticancer Therapy。你们前面用依维莫斯,血、肝肾功能还好。下一步是否考虑索拉非尼+依维莫斯。供你参考。
- }8 r( ]: [* C& b. @
/ c2 x( k: w0 d- K* w+ \/ G& b
' t8 ~5 B4 Z2 BCurrently available feasibility data for possible combination strategies.
- R @9 S* J8 M) w8 W————————————————————————————————
9 A. i) s) f1 F+ c2 v9 U- bCombination Feasibility according to preliminary data
% s) g: F X1 T- ^+ J! c+ H——————————————————————————————————
( t+ P: [0 i( u- r |6 G8 jBevacizumab + sorafenib Yes, reduced dose
0 }( C2 Z7 }) g1 B5 g6 fBevacizumab + sunitinib† No
* Z) R0 x( o! u9 A* r" JBevacizumab + temsirolimus Yes
% T2 j) J8 H, h3 { ]1 d% w7 h: ~Bevacizumab + everolimus Yes + x n" m( I) D% J
Sorafenib + sunitinib ?
, o8 t n4 L) R zSorafenib + temsirolimus Yes, reduced dose $ N3 \! B% \3 k5 e- }, v6 e. D
Sorafenib + everolimus Yes, reduced dose 0 ?3 R# u' S1 w5 z* m
Sunitinib + temsirolimus† No . B# J2 \0 r {" P( [
Sunitinib + everolimus ? 8 L& h1 R6 ^; s
Temsirolimus + everolimus ? 8 v9 I' B0 o; N) w7 q& V4 F) i$ r; Q% O
————————————————————
" W; [8 n: c& m1 H†Led to US FDA warning.; q% ~& h7 V8 p4 g* x% {
?: As yet unattempted combination.. X* ?, W4 ^$ J7 g6 k3 ]/ ~
|